Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications

Archives of Pediatrics and Adolescent Medicine

Volumn 165, Issue 6, 2011, Pages 498-505

  Hampp, Christian ^a   Kauf, Teresa L ^b   Saidi, Arwa S ^c   Winterstein, Almut G ^b,d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NEWBORN; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PRIMARY PREVENTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 79958047927     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2010.298     Document Type: Article

References (30)

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282 (15):1440-1446.
3. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR; 2010.
4. Committee on Infectious Diseases. Policy statements: modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701.
5. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children. Arch Pediatr Adolesc Med. 2002;156(12):1251-1255. (Pubitemid 36343445)
6. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070-1076. (Pubitemid 44520638)
7. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114(6):1612-1619. (Pubitemid 41754927)
8. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther. 1999;21(4):752-766. (Pubitemid 29252097)
9. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther. 2000;22(11):1357-1369.
10. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156(10):1034-1041. (Pubitemid 36343482)
11. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6, pt 1):1442-1446.
12. American Academy of Pediatrics: dedicated to the health of all children. Fact sheet: children's health insurance. American Academy of Pediatrics Web site. http://www.aap.org/research/factsheet.pdf. Accessed July 30, 2010.
13. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-517. (Pubitemid 351973995)
14. Hampp C, Saidi AS, Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953-959.
15. Hampp C, Saidi A, Winterstein AG. Latitude as a factor in RSV epidemiology in Florida. Paper presented at: 43rd Annual Meeting of the Society of Epidemiologic Research; June 23-26, 2010; Seattle, WA.
16. Pharmacy prior authorization forms. Florida Agency for Healthcare Administration Web site. http://ahca.myflorida.com/medicaid/Prescribed-Drug/ pharm-thera/paforms.shtml. Accessed December 22, 2008.
17. Most requested statistics. Consumer Price Index. Bureau of Labor Statistics Web site. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed November 15, 2010.
18. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3, pt 1):531-537.
19. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540. (Pubitemid 37352516)
20. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104 (3, pt 1):419-427. (Pubitemid 29424659)
21. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother. 2001;35(10):1186-1193. (Pubitemid 32959184)
22. Stensballe LG, Simonsen JB, Thomsen SF, et al. The causal direction in the association between respiratory syncytial virus hospitalization and asthma. J Allergy Clin Immunol. 2009;123(1):131-137.
23. Thomsen SF, van der Sluis S, Stensballe LG, et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. Am J Respir Crit Care Med. 2009;179(12):1091-1097.
24. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183(1):16-22.
25. Swedish Consensus Group.Management of infections caused by respiratory syncytial virus. Scand J Infect Dis. 2001;33(5):323-328.
26. Vogel AM, Lennon DR, Broadbent R, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health. 2002;38(6):550-554. (Pubitemid 35370559)
27. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants: is it worth it? Arch Dis Child Fetal Neonatal Ed. 2005;90(4):F286-F289.
28. Navér L, Eriksson M, Ewald U, Linde A, Lindroth M, Schollin J. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Paediatr. 2004;93(11):1470-1473. (Pubitemid 39457061)
29. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR; 2004.
30. Drug Utilization Review Board. Florida Agency for Healthcare Administration Web site. http://ahca.myflorida.com/Medicaid/Prescribed-Drug/ board.shtml. Accessed March 24, 2010.